Leishmaniasis: New approaches to disease control

British Medical Journal

Volumn 326, Issue 7385, 2003, Pages 377-382

  Davies, Clive R ^a   Kaye, Paul ^a   Croft, Simon L ^a   Sundar, Shyam ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; ANTIRETROVIRUS AGENT; CYHALOTHRIN; GENTAMICIN; INSECTICIDE; KETOCONAZOLE; LEISHMANIA VACCINE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; PLACEBO; PYRETHROID; SITAMAQUINE;

ANTIGEN DETECTION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG FORMULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSECT CONTROL; LATEX AGGLUTINATION TEST; LEISHMANIA; LEISHMANIASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTOZOAL INFECTION; REVIEW; SKIN LEISHMANIASIS; VACCINATION; VISCERAL LEISHMANIASIS; ZOONOSIS;

EID: 0037442697     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.326.7385.377     Document Type: Review

References (28)

1. World Health Organization. Annex 3: Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2001. In: The world health report. Geneva: WHO, 2002: 192-7. (www.who.int/whr/2002/whr2002_annex3.pdf)
2. Sundar S, Reed SG, Singh VP, Kumar PCK, Murray HW. Rapid accurate field diagnosis of visceral leishmaniasis. Lancet 1998;351:563-5.
3. Zijlstra E.E, Nut Y, Desjeux P, Khalil EA, el Hassan AM, Groen J. Diagnosis of visceral leishmaniasis with the recombinant k39 strip test: experience from Sudan. Trop Med Int Health 2001;6:108-13.
4. Attar ZJ, Chance ML, el Safi S, Carney J, Azazy A, El Hadi M, et al. Latex agglutination test for detection of urinary antigens in visceral leishmaniasis. Acta Trop 2001;78:11-6.
5. Martin Sanchez J, Lopez-Lopez MC, Acedo-Sanchez C, Castro-Fajardo JJ, Pineda JA, Morillas-Marquez F. Diagnosis of infection with Leishmania infantum using PCR-ELISA. Parasitology 2001;122:607-15.
6. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makhariz A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Infect Dis 2000;31:1104-7.
7. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusion of low dose liposomal amphotericin B: randomised trial. BMJ 2001;323:419-22.
8. v for treating visceral leishmaniasis in north Bihar, India. BMJ 1998;316:1200-5.
9. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999;341:1795-1800.
10. De La Rosa R, Pineda JA, Delgado J, Macias J, Morillas F, Mira JA, et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active anfiretroviral therapy. J Clin Microbiol. 2002;40:762-7.
11. Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001;33:1847-51.
12. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001;33:e57-61.
13. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002;346:891-5.
14. Reyburn H, Ashford R. Mohsen M, Hewitt S, Rowland M. A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Trans R Soc Trop Med Hyg 2000;94:361-6.
15. Davies CR, Llanos-Cuentas EA, Campos P, Monge J, Leon E, Canales J. Spraying houses in the Peruvian Andes with lambda-cyhalothrin protects residents against cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2000;94:631-6.
16. Bern C, Joshi AB, Jha SN, Das ML, Hightower A, Thakur GD, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 2000;63:184-8.
17. Tayeh A, Jalouk L, Al-Khiami AM. A cutaneous leishmaniasis control trial using pyrethroid-impregnated bednets in villages near Aleppo, Syria. Geneva: World Health Organization, 1997. (WHO/LEISH/97.41.)
18. Ashford DA, David JR, Freire M. David R, Sherlock I, Eiulalio MC, et al. Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg 1998;59:53-7.
19. Reithinger R, Quinnell RJ, Alexander B, Davies CR. Rapid detection of Leishmania infantum infection in dogs: comparative study using an immunochromatographic dipstick test, enzyme-linked immunosorbent assay, and PCR. J Clin Microbiol 2002;40:2352-6.
20. Reithinger R, Teodoro U, Davies CR. A comparative trial of topical insecticide treatments to protect dogs from bites of sandfly vectors of leishmaniasis. Emerg Infect Dis 2001;7:872-6.
21. Mazloumi Gavgani AS, Hodjati MH, Mohite H, Davies CR. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet 2002;360:374-9.
22. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001;14:229-43.
23. Kenney RT, Sacks DL, Sypek JP. Vilela L, Gam AA, Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999;163:4481-8.
24. Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E. Bertholet S, et al., CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002;168:3992-4000.
25. Rhee EG, Mendez S, Shah JA, Wu CV, Kirman JR, Turon TN, et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 2002;195:1565-73.
26. Melhy PC, Yang J, Zhao W, Perez LE, Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immunol 2001;69:4719-25.
27. Khalil EA, El Hassan AM. Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000;356:1565-9.
28. Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol 2001;100:87-103.